LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid therapeutics for the treatment of diseases with significant unmet medical need, announced results for its half-year ended June 30, 2021.
August 12, 2021
· 15 min read